Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Register now >>

Non-Clinicians / Medical Office Support Staff / Industry Participants

Non-clinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff—may attend PAINWeekEnd on a space-available basis when accompanied by a clinician and will be put on a wait list. These non-clinicians must still pre-register. Participation in industry sponsored meal programs, however, is strictly limited to practicing licensed healthcare providers. Please make necessary arrangements for meals for office support staff. In order to maintain the professional nature of the conference, guests, spouses, friends, and/or family members who are not currently employed in the medical field may not attend PAINWeekEnd.

Venue

Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

DoubleTree by Hilton Hotel Denver Tech Center
7801 E Orchard Rd.
Greenwood Village, CO 80111

View hotel website >>

Directions

Get Directions using Google Maps

Agenda

Download a printable version of the agenda >>

Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.

To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

*not certified for credit

Saturday, March 30, 2019

  • REGISTRATION & EXHIBITS

    Coffee will be served.

  • Nonopioid Analgesics: Antidepressants, Adjuvant Therapies, and Muscle Relaxants

    Nonopioid analgesics are considered first-line therapy for most chronic pain syndromes. A strong recall of these agents’ safety and efficacy profiles is paramount for today’s pain practitioner. This course will provide an in-depth look at each of the agents within these drug classes, their potential role in pain management, and available data supporting their use. Additionally, clinically relevant monitoring will be discussed.

    • UAN: 0530-0000-19-046-L01-P
    • AANP Rx Hours: 1.00
  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Breakfast will be served.

    Sponsored by Teva Pharmaceuticals.

  • BREAK & EXHIBITS

  • Involuntary Tapers: Legal, Ethical, and Clinical Concerns

    On March 15, 2016, the Centers for Disease Control and Prevention released their guideline with recommendations for primary care clinicians who prescribe opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Although most of the recommendations were supported by weak or very weak evidence, Recommendation # 7 stated that “clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids” if the harms outweigh the benefits. At least a year after the release of the CDC guideline, several states have implemented dosage triggers, ceilings, and involuntary tapers, and some healthcare professionals have reportedly subjected their patients to involuntary tapers because they believed the CDC guideline required it. Consequently, this session will explore the ethical, legal, and clinical concerns and potential harms associated with the involuntary tapering of patients on long-term opioid therapy as a result of a state law, regulation, or out of fear of regulatory sanction by the healthcare provider.

    • UAN: 0530-0000-19-010-L01-P
    • AANP Rx Hours: 0.00
  • Embrace Changes and Prevent Overdose: A Basic Blueprint for Legal Risk Mitigation and Response

    Overdose—a small word that packs a major punch, and a big reason for many recent legal regulatory changes in controlled substance prescribing and pain management. Too many physicians and allied healthcare practitioners are caught unawares by the legal issues surrounding overdose events, fatal and nonfatal. Often, prescribers are the last to learn about an overdose event and, worse yet, fail to take action once notified. Through a series of case examples, attendees will learn how to develop and implement overdose event policies and protocols. Attendees will receive copies of sample policies and protocols and learn how to tailor them to their respective practices and state licensing board framework. Professional licensing board and criminal cases involving overdose events do not usually end well for the prescriber, but there is much the prescriber can do proactively to signal his/her intent to get things right. While prescribers cannot control what their patients do once they leave the medical office, they are responsible for establishing a safe framework for opioid prescribing, including a proper response when something goes wrong.

    • UAN: 0530-0000-19-008-L01-P
    • AANP Rx Hours: 0.00
  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

    Sponsored by SCILEX.

  • Rational Polypharmacy: An Update for Specific Conditions

    Rational polypharmacy or the use of multiple medications to manage the same disease state or condition has been a part of treatment approaches for chronic pain for many years. This course will review the concept of rational polypharmacy as it applies to the treatment of migraine, neuropathic pain, and musculoskeletal pain conditions.

    • UAN: 0530-0000-19-032-L01-P
    • AANP Rx Hours: 0.00
  • BREAKS & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

  • Cannabis vs Cannabinoids: The Politics of Medical Marijuana

    The subject of the medical use of cannabinoids has become an extremely hot topic. Unfortunately, there has been a tendency to equate medical cannabinoids with another very contentious topic: Medical Marijuana. In this presentation, the distinction between medical cannabinoids and medical cannabis will be explored. Specifically, the challenges facing prescribers who are being asked to prescribe medical marijuana will be examined.

    • UAN: 0530-0000-19-007-L01-P
    • AANP Rx Hours: 0.00
  • Get Your Specimens in Order: Timely Use of Test Results

    2018 was not a good year to be on the wrong side of medical necessity when it came to drug testing and ongoing prescribing of controlled medication or substance abuse treatment programs. 2019 is likely to be an expensive year for those who do not proactively take steps to understand medical necessity for drug testing, prescribing controlled medication, and ongoing substance abuse treatment, as payers continue to carefully scrutinize these areas. Using a series of case hypotheticals, attendees will learn how to identify the elements of medical necessity, efficiently and effectively document medical necessity for drug testing and use of drug test results in the ongoing care of the patient, and locate and use payer medical policies and coverage determinations. Attendees will be given 3 tools to reinforce learning objectives: a checklist for medical necessity documentation, sample summaries of payer medical policies, and templates for documenting use of drug test results and tailoring ongoing treatment decisions to the individual patient.>

    • UAN: 0530-0000-19-009-L01-P
    • AANP Rx Hours: 0.00

SPONSORED PROGRAMS

To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!